Anuncios
U.S. markets close in 7 minutes

  • S&P 500

    5,103.16
    +54.74 (+1.08%)
     

  • Dow Jones

    38,259.18
    +173.38 (+0.46%)
     

  • Nasdaq

    15,936.86
    +325.10 (+2.08%)
     

  • Russell 2000

    2,001.65
    +20.53 (+1.04%)
     

  • Petróleo

    83.64
    +0.07 (+0.08%)
     

  • Oro

    2,349.40
    +6.90 (+0.29%)
     

  • Plata

    27.20
    -0.15 (-0.54%)
     

  • dólar/euro

    1.0701
    -0.0032 (-0.30%)
     

  • Bono a 10 años

    4.6690
    -0.0370 (-0.79%)
     

  • dólar/libra

    1.2494
    -0.0017 (-0.13%)
     

  • yen/dólar

    157.8700
    +2.2900 (+1.47%)
     

  • Bitcoin USD

    63,876.23
    -767.54 (-1.19%)
     

  • CMC Crypto 200

    1,330.27
    -66.26 (-4.75%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Nikkei 225

    37,934.76
    +306.28 (+0.81%)
     

2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

Prosper Junior Bakiny, The Motley Fool
·4  min de lectura
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.

Continuar leyendo